Dianthus (DNTH) Therapeutics announced the appointment of John King as Chief Commercial Officer. King brings more than 25 years of global commercial leadership experience within biotechnology, including complement inhibitor experience in neuromuscular and hematological rare diseases. In this newly created position, King will play a critical role in the Company’s corporate and commercial strategy.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks